Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MW032 vs Xgeva in Bone Metastases from Solid Tumors
NCT04812509Phase 3Completed
- Sponsor
- Mabwell
- Start
- Mar 2020
- Primary completion
- Apr 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant human papillomavirus nonavalent vaccine in bone metastases, sponsored by Mabwell. Started Mar 2020; status: completed.
02
Drugs
recombinant human papillomavirus nonavalent vaccine
03
Conditions
bone metastases
Beyond the preview
Go deeper on NCT04812509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04812509.